清瘟败毒饮对兔全身炎症反应综合征的介质组调节机制研究
|
摘要
研究目的:
“炎症介质组”是指一个细胞或一个组织在单一时相点的全部炎症介质,在感染过程中常常被高度表达。之所以将这些炎症介质称为“组”,是因为它们由于功能上的紧密联系而构成了一个相对独立的有机整体。本研究从海量的蛋白质种类中挑选部分指标作为明确的研究靶点,由于研究范围的缩窄,指标的测量可以改用比较精确、直接的方法,而数据处理的难度也相对降低。这样可以克服目前整体生物学技术和数据处理技术的局限性,对于整体分析研究中医治疗机制具有重要意义。
全身炎症反应综合征(SIRS)中的失控性炎症,实际上是一种介质病,主要由细胞因子链锁反应所致。但是至今为止,拮抗炎症介质治疗感染性休克未能取得确切疗效。研究失败的原因可能有二:第一,炎症介质种类很多,目前已知有30多种,仅针对其中个别的炎症介质治疗不能改变病情。第二,炎症介质本身可能在感染性休克的发展中对机体有一定的保护作用,抑制炎症介质的同时也促进了感染对机体的损伤。
解决策略如下:针对第一种原因,解决策略是干预多种炎症介质。针对第二种原因,解决策略是精确干预。不是盲目地清除或拮抗炎症介质,而是在病程每个时相点对炎症介质采取正确和适度的治疗。同时对多种炎症介质进行精确干预是最理想的治疗策略,称之为“介质组调节”,中医药由于其整体作用特点而有可能具备这种“介质组调节”的治疗机制。清瘟败毒饮和醒脑静治疗温病疗效肯定,已经被证明可以影响多种炎症介质水平,故拟通过本研究探索清瘟败毒饮和醒脑静对SIRS实验动物模型炎症介质组的影响。
研究方法:
本研究是一项使用清瘟败毒饮和醒脑静治疗SIRS,并较大规模地平行检测多种血清炎症介质的实验,共包括4个部分。
在“实验一”中,探索了不同剂量和不同次数注射脂多糖(LPS)制作新西兰兔温病实验动物模型的方法。
在“实验二”中,通过间隔24h的2次LPS注射法(施瓦茨曼法)制作新西兰兔SIRS模型,使用含有不同剂量生石膏的清瘟败毒饮灌胃治疗。治疗后第1、2.5、5.5h测量肛温,观察神志、皮肤粘膜改变和其他症状;治疗后1、2.5h耳动脉采血,采用酶联免疫吸附法测定促炎介质IL-1、IL-6、IL-12、IL-18、TNF-α、IFN-γ和抑炎介质IL-4、IL-10、IL-13、TGF-β1;并进行病理检查。
在“实验三”中,使用与实验二中相同的动物模型,使用醒脑静注射液耳缘静脉注射治疗SIRS。治疗后第1、2.5、5.5h测量肛温,观察神志、皮肤粘膜改变和其他症状;治疗后1、2.5h耳动脉采血,采用酶联免疫吸附法测定促炎介质IL-1、IL-6、IL-12、IL-18、TNF-α、IFN-γ和抑炎介质IL-4、IL-10、IL-13、TGF-β1;并进行病理检查。
在“实验四”中,通过双变量相关分析、偏相关分析、聚类分析、因子分析、多元线性回归分析和Logistic回归分析等多元统计学方法研究实验一、二、三中49只新西兰兔的炎症介质检测指标和体温,探索炎症介质组的变化规律。
研究结果:
在不同剂量注射实验中,1次注射后实验动物出现发热、少动倦怠、呼吸增快等;2次注射后仍可出现发热、少动倦怠和呼吸增快,伴随耳缘静脉出血时间延长;随着注射脂多糖剂量增加,病情有加剧的趋势,大剂量注射后出现精神极度萎靡、耳缘冰冷等内毒素休克的表现,易导致死亡。在多次注射实验中,在7日中,等量或递增剂量的LPS每日1次注射均可引起发热。在验证实验中,第1次注射LPS后全部38只兔出现发热,其中2只于24h内死亡,再次注射LPS后,全部兔再次出现发热,继续观察48h,未再出现死亡。
含有不同剂量生石膏的清瘟败毒饮治疗后1、2.5h,治疗组体温均低于对照组,差别有统计学意义。在治疗后1h,大剂量组的TNF-α水平低于对照组,TGF-β1水平高于对照组,差别有统计学意义,在全部炎症介质中,小剂量组的炎症介质水平常常介于对照组和大剂量组之间,而对照组的炎症介质水平从不会位于小、大剂量组之间。在治疗后2.5h,大剂量组的TNF-α水平低于对照组,差别有统计学意义,小、大剂量组的IL-4水平均高于对照组,差别接近有统计学意义(P=0.056),小剂量组的炎症介质水平同样常常介于对照组和大剂量组之间。
醒脑静治疗后1、2.5h体温均低于对照组,差别有统计学意义。醒脑静治疗后1h醒脑静组的TNF-α水平低于对照组,IL-18水平高于对照组,差别有统计学意义。醒脑静治疗后2.5h各种炎症介质的组间差别均无统计学意义。
各治疗组相对于对照组的炎症介质变化趋势的比较结果显示,炎症介质组的变化具有一定的规律性,特别是对于小、大剂量的清瘟败毒饮组来说,几乎各时限所有的炎症介质改变的方向都是相同的。积矩相关系数、等级相关系数和偏相关系数的计算结果显示,各种抑炎介质之间均呈正相关,各种促炎介质之间多呈正相关,而促炎介质与抑炎介质之间的相关关系则比较复杂,部分炎症介质之间相关系数较高。指标聚类的结果显示,第一步将IL-12与IL-13聚为一类,第二步将IL-12、IL-13与TGF-β1聚为一类,共进行9步,最后一步将TNF-α与其他炎症介质聚类。因子分析得到3个公因子:第一个公因子包括IL-12、IL-13、TGF-β1、IL-4共4种炎症介质,第二个公因子包括IFN-γ、TNF-α、IL-18、IL-10共4种炎症介质,第三个公因子包括IL-1、IL-6、IL-10共3种炎症介质。在全变量回归分析、逐步回归分析和二分类逐步logistic回归分析中,均得到了有统计学意义的回归方程模型,但决定系数较低,有统计学意义的变量较少。
结论:
LPS致热效果肯定,不同剂量、不同次数的LPS注射可以成功制作卫、气、营、血各阶段动物模型。卫气分模型宜用单次静脉注射法,营血分或气血两燔证模型用间隔24h的两次LPS注射法,长期发热的温病模型如留恋气分证或肝肾阴伤证可用多次注射法,内闭外脱证模型使用大剂量LPS注射。
含有不同剂量生石膏的清瘟败毒饮均具有退热作用,其中以大剂量组的退热作用更为显著。清瘟败毒饮的作用机制可能包括抑制促炎介质TNF-α和提升抑炎介质TGF-β1,因而具有抗炎作用。全部炎症介质数据的分布表现出较明显的规律性,提示含有不同剂量生石膏的清瘟败毒饮可能致使介质水平向着相同的方向改变,大剂量组的改变更为显著。
醒脑静具有退热作用。醒脑静能够降低促炎介质TNF-α水平而抗炎,而提升IL-18水平的意义不明。
炎症介质变化方向的规律性提示各组药物对介质组的作用机制有相似之处;各种炎症介质之间具有比较密切的关系;指标聚类的结果提示,IL-12、IL-13与TGF-β1的数据相似程度最高,而TNF-α的数据特点与其他炎症介质有较大区别;因子分析结果中的第一个公因子主要反映抑炎介质,而第二、三个公因子主要反映不同的促炎介质,提示了炎症介质组的变化特点。
Objective:
"Inflammatory Mediatorome",usually highly expressed during inflammation, were all mediators of inflammation in a cell or tissue in one time-phase.As an organic whole,mediators of inflammation,closely linked in function,were called "mediatorome" In this research,several kinds of protein were selected to study from a great deal kinds of protein.Because studying target was limited in a small circumscription,experimental detection could be finished by precise technique and data processing would be easy.This strategy was helpful to resolve problems both in experimental techniques and data processing and very important in TCM research by holistic cellular biology techniques.
Uncontrolled inflammation in systemic inflammatory response syndrome(SIRS) was actually a mediator disease,mainly caused by chain reaction of cytokine.But up to now,no anti-mediator therapy had made sure effect in treating septic shock.There were two possible reasons.First,there were so many kinds of mediator of inflammation that pathogenetic condition could not be improved by treating only a few mediators.Second,mediators of inflammation could protect the body in septic shock and anti-mediator therapy could destroy the protection.
For the first reason,many kinds of mediators of inflammation should be treated together。For the second reason,every mediator in every time-phase should be treated correctly and moderately instead of being simply cleaned up.Exactly treating many kinds of mediators together was a ideal strategy, which was called "mediatorome regulating".TCM could regulate the mediatorome because of its integrity characteristics.Decoction for clearing away pestilent factors and detoxification(DCPD) and Xingnaojing injection(XNJI) had sure therapeutic effect to exogenous febrile disease and could affect mediators.In this research,SIRS experimental animals were treated by DCPD and XNJI while the change of mediatorome was observed and analyzed.
Method:
This research,in which SIRS experimental animals were treated by DCPD and XNJI while many kinds of mediator of inflammation were detected,included 4 experiments.
In "experiment 1",New Zealand rabbits received LPS injection of different times and different doses to indue different exogenous febrile disease model.
In "experiment 2",New Zealand rabbits SIRS models were induced by twice(with a 24-hour interval) lipopolysaccharide(LPS) infusion through vein.SIRS rabbits received intragastric administration of DCPD containing different dose of gypsum.Symptoms and objective signs,such as rectal temperature,consciousness,skin and mucosa,were observed at 1,2.5 and 5.5 hour after dosage and blood samples were collected at 1 and 2.5 hour after dosage.Then,10 kinds of cytokines,including interleukin1(IL-1), interleukin4(IL-4),interleukin6(IL-6),interleukin10(IL-10), interleukin12(IL-12),interleukin13(IL-13),interleukin18(IL-18),tumor necrosis factor-α(TNF-α),interferon-γ(INF-γ) and transforming growth factor(TGF-β1),were tested by enzyme linked immunosorbent assay.Samples of lung and liver were got for pathological section at the end of experiment.
In "experiment 3",SIRS models,indueed in the same way,received XNJI intravenous injection in ear vein.Symptoms and objective signs,such as rectal temperature,consciousness,skin and mucosa,were observed at 1,2.5 and 5.5 hour after dosage and blood samples were collected at 1 and 2.5 hour after dosage.Then,10 kinds of cytokines,including IL-1,IL-4,IL-6,IL-10,IL-12, IL-13,IL-18,TNF-α,INF-γand TGF-β1,were tested by enzyme linked immunosorbent assay.Samples of lung and liver were also got for pathological section.
In "experiment 4",the level of inflammatory mediators and rectal temperature of 49 rabbits in other three experiments were analyzed through bivariate correlate,partial correlate,hierarchical cluster,factor date reduction,linear regression and Logistic regression to explore the variation rule of inflammatory mediatorome.
Results:
In the different-dose injecting experiment,the first LPS injection caused fever,less activity,lassitude and tachypnea in rabbits,then similar symptoms accompanied with prolonged venous hemorrhage time were found after the second injection.As the LPS dose increasing,pathogenetic condition intensified.Large-dose LPS injection caused endotoxin shock symptoms such as unconsciousness and ice cold ears,possibly causing death.In the multiple injecting experiment,injection with equal dose or progressively increasing dose could induce fever every time during 7 days.In the validity proving experiment,all the 38 rabbits had fever after first injection and 2 rabbits died in 24 hours,then all the remained 36 rabbits had fever again after second injection and no rabbit died in next 48 hours.
The DCPD treated groups received intragastric administration of DCPD containing different dose of gypsum.Rectal temperature of both the little-dose and large-dose DCPD group was lower than the controlled group at 1h and 2.5h after dose and there was statistical significance in the difference. At 1h after dose,TNF-αlever of the large-dose DCPD group was lower than the controlled group while TGF-β1 lever was higher,the difference was statistically significant.Lever of inflammatory mediators in little-dose DCPD group was usually between the controlled group and large-dose DCPD group, while lever of inflammatory mediators in the controlled group was never between the little-dose and large-dose DCPD group.At 2.5h after dose,TNF-αlever of large-dose DCPD group was significantly lower than the controlled group, while IL-4 lever of both the little-dose and large-dose DCPD group was higher than the controlled group,the difference is nearly significant(P= 0.056).Lever of inflammatory mediators in little-dose DCPD group was usually between the other 2 groups.
Rectal temperature of the XNJI treated group was significantly lower than the controlled group at 1h and 2.5h after dose.At 1h after dose,TNF-αlever of the XNJI treated group was lower than the controlled group and IL-18 lever was higher,the difference was statistically significant.At 2.5h after dose, no statistical significance was obtained in all the inflammatory mediators between 2 groups.
Variation tendency of inflammatory mediators in all the treated groups was compared to the controlled group and variation of inflammatory mediatorome showed some regularity.For the 2 DCPD treated groups,the direction of variation of all the inflammatory mediators at different time-phase was almost same.According to Pearson coefficient correlation,Spearman coefficient correlation and partial coefficient correlation,positive correlation was found between pro-inflammatory mediators and between anti-inflammatory mediators,but correlation between pro-inflammatory mediators and antiinflammatory mediators was complicated.The coefficient correlation was high between several mediators.In a 9-step clustering analysis,IL-12 and IL-13 were clustered at the first step,IL-12,IL-13 and TGF-β1 were clustered at the second step,while TNF-αwas clustered with other inflammatory mediators at the last step.3 common factors were obtained in factor analysis.The first common factor included IL-12、IL-13、TGF-β1 and IL-4,the second common factor included IFN-γ、TNF-α、IL-18 and IL-10,while the last common factor consisted IL-1、IL-6 and IL-10.Regression equations obtained by linear regression and logistic regression were statistically significant,but coefficients of determination were poor and only a few variables had statistical significance.
Conclusion:
LPS injection could surely cause fever.LPS injection with different times and different doses could indue different exogenous febrile disease models of Weifen,qifen,yingfen and xuefen syndrome.Weifen and qifen syndrome could be endued by LPS infusion once,yingfen and xuefen syndrome could be endued by twice(with a 24-hour interval) LPS infusion,persistent qifen syndrome or deficiency of liver-yin and kidney-yin syndrome by multiple times infusion and unconsciousness and collapse syndrome could be caused by large-dose LPS injection.
The results showed that DCPD containing different dose of gypsum gave antipyretic effect on SIRS rabbits and DCPD containing large dose of gypsum gave more obvious antipyretic effect.DCPD could antagonise inflammation possibly by restraining TNF-αand promoting TGF-β.All the data of inflammatory mediators showed regularity.DCPD with different dose of gypsum caused inflammatory mediators changing in the same direction and the effect of DCPD with large dose of gypsum was more obvious.
The results showed that XNJZ also gave antipyretic effect on SIRS rabbits and antagonised inflammation possibly by restraining TNF-α,but the reason about promoting IL-18 was unknowed.
Some variation characteristic of inflammatory mediatorome was revealed through several multivariate statistical analyzing.The regularity of variation of inflammatory mediators suggested that action mechanism of different treating drugs could be similar.Correlation analysis demonstrated that inflammatory mediators had close relationship.Clustering analysis showed that numerical data of IL-12,IL-13 and TGF-β1 was very similar and data characteristic of TNF-αwas quite different.3 common factors were obtained in factor analysis.The first common factor mainly reflected anti-inflammatory mediators,while the second and third common factors probably reflected different pro-inflammatory mediators.
“炎症介质组”是指一个细胞或一个组织在单一时相点的全部炎症介质,在感染过程中常常被高度表达。之所以将这些炎症介质称为“组”,是因为它们由于功能上的紧密联系而构成了一个相对独立的有机整体。本研究从海量的蛋白质种类中挑选部分指标作为明确的研究靶点,由于研究范围的缩窄,指标的测量可以改用比较精确、直接的方法,而数据处理的难度也相对降低。这样可以克服目前整体生物学技术和数据处理技术的局限性,对于整体分析研究中医治疗机制具有重要意义。
全身炎症反应综合征(SIRS)中的失控性炎症,实际上是一种介质病,主要由细胞因子链锁反应所致。但是至今为止,拮抗炎症介质治疗感染性休克未能取得确切疗效。研究失败的原因可能有二:第一,炎症介质种类很多,目前已知有30多种,仅针对其中个别的炎症介质治疗不能改变病情。第二,炎症介质本身可能在感染性休克的发展中对机体有一定的保护作用,抑制炎症介质的同时也促进了感染对机体的损伤。
解决策略如下:针对第一种原因,解决策略是干预多种炎症介质。针对第二种原因,解决策略是精确干预。不是盲目地清除或拮抗炎症介质,而是在病程每个时相点对炎症介质采取正确和适度的治疗。同时对多种炎症介质进行精确干预是最理想的治疗策略,称之为“介质组调节”,中医药由于其整体作用特点而有可能具备这种“介质组调节”的治疗机制。清瘟败毒饮和醒脑静治疗温病疗效肯定,已经被证明可以影响多种炎症介质水平,故拟通过本研究探索清瘟败毒饮和醒脑静对SIRS实验动物模型炎症介质组的影响。
研究方法:
本研究是一项使用清瘟败毒饮和醒脑静治疗SIRS,并较大规模地平行检测多种血清炎症介质的实验,共包括4个部分。
在“实验一”中,探索了不同剂量和不同次数注射脂多糖(LPS)制作新西兰兔温病实验动物模型的方法。
在“实验二”中,通过间隔24h的2次LPS注射法(施瓦茨曼法)制作新西兰兔SIRS模型,使用含有不同剂量生石膏的清瘟败毒饮灌胃治疗。治疗后第1、2.5、5.5h测量肛温,观察神志、皮肤粘膜改变和其他症状;治疗后1、2.5h耳动脉采血,采用酶联免疫吸附法测定促炎介质IL-1、IL-6、IL-12、IL-18、TNF-α、IFN-γ和抑炎介质IL-4、IL-10、IL-13、TGF-β1;并进行病理检查。
在“实验三”中,使用与实验二中相同的动物模型,使用醒脑静注射液耳缘静脉注射治疗SIRS。治疗后第1、2.5、5.5h测量肛温,观察神志、皮肤粘膜改变和其他症状;治疗后1、2.5h耳动脉采血,采用酶联免疫吸附法测定促炎介质IL-1、IL-6、IL-12、IL-18、TNF-α、IFN-γ和抑炎介质IL-4、IL-10、IL-13、TGF-β1;并进行病理检查。
在“实验四”中,通过双变量相关分析、偏相关分析、聚类分析、因子分析、多元线性回归分析和Logistic回归分析等多元统计学方法研究实验一、二、三中49只新西兰兔的炎症介质检测指标和体温,探索炎症介质组的变化规律。
研究结果:
在不同剂量注射实验中,1次注射后实验动物出现发热、少动倦怠、呼吸增快等;2次注射后仍可出现发热、少动倦怠和呼吸增快,伴随耳缘静脉出血时间延长;随着注射脂多糖剂量增加,病情有加剧的趋势,大剂量注射后出现精神极度萎靡、耳缘冰冷等内毒素休克的表现,易导致死亡。在多次注射实验中,在7日中,等量或递增剂量的LPS每日1次注射均可引起发热。在验证实验中,第1次注射LPS后全部38只兔出现发热,其中2只于24h内死亡,再次注射LPS后,全部兔再次出现发热,继续观察48h,未再出现死亡。
含有不同剂量生石膏的清瘟败毒饮治疗后1、2.5h,治疗组体温均低于对照组,差别有统计学意义。在治疗后1h,大剂量组的TNF-α水平低于对照组,TGF-β1水平高于对照组,差别有统计学意义,在全部炎症介质中,小剂量组的炎症介质水平常常介于对照组和大剂量组之间,而对照组的炎症介质水平从不会位于小、大剂量组之间。在治疗后2.5h,大剂量组的TNF-α水平低于对照组,差别有统计学意义,小、大剂量组的IL-4水平均高于对照组,差别接近有统计学意义(P=0.056),小剂量组的炎症介质水平同样常常介于对照组和大剂量组之间。
醒脑静治疗后1、2.5h体温均低于对照组,差别有统计学意义。醒脑静治疗后1h醒脑静组的TNF-α水平低于对照组,IL-18水平高于对照组,差别有统计学意义。醒脑静治疗后2.5h各种炎症介质的组间差别均无统计学意义。
各治疗组相对于对照组的炎症介质变化趋势的比较结果显示,炎症介质组的变化具有一定的规律性,特别是对于小、大剂量的清瘟败毒饮组来说,几乎各时限所有的炎症介质改变的方向都是相同的。积矩相关系数、等级相关系数和偏相关系数的计算结果显示,各种抑炎介质之间均呈正相关,各种促炎介质之间多呈正相关,而促炎介质与抑炎介质之间的相关关系则比较复杂,部分炎症介质之间相关系数较高。指标聚类的结果显示,第一步将IL-12与IL-13聚为一类,第二步将IL-12、IL-13与TGF-β1聚为一类,共进行9步,最后一步将TNF-α与其他炎症介质聚类。因子分析得到3个公因子:第一个公因子包括IL-12、IL-13、TGF-β1、IL-4共4种炎症介质,第二个公因子包括IFN-γ、TNF-α、IL-18、IL-10共4种炎症介质,第三个公因子包括IL-1、IL-6、IL-10共3种炎症介质。在全变量回归分析、逐步回归分析和二分类逐步logistic回归分析中,均得到了有统计学意义的回归方程模型,但决定系数较低,有统计学意义的变量较少。
结论:
LPS致热效果肯定,不同剂量、不同次数的LPS注射可以成功制作卫、气、营、血各阶段动物模型。卫气分模型宜用单次静脉注射法,营血分或气血两燔证模型用间隔24h的两次LPS注射法,长期发热的温病模型如留恋气分证或肝肾阴伤证可用多次注射法,内闭外脱证模型使用大剂量LPS注射。
含有不同剂量生石膏的清瘟败毒饮均具有退热作用,其中以大剂量组的退热作用更为显著。清瘟败毒饮的作用机制可能包括抑制促炎介质TNF-α和提升抑炎介质TGF-β1,因而具有抗炎作用。全部炎症介质数据的分布表现出较明显的规律性,提示含有不同剂量生石膏的清瘟败毒饮可能致使介质水平向着相同的方向改变,大剂量组的改变更为显著。
醒脑静具有退热作用。醒脑静能够降低促炎介质TNF-α水平而抗炎,而提升IL-18水平的意义不明。
炎症介质变化方向的规律性提示各组药物对介质组的作用机制有相似之处;各种炎症介质之间具有比较密切的关系;指标聚类的结果提示,IL-12、IL-13与TGF-β1的数据相似程度最高,而TNF-α的数据特点与其他炎症介质有较大区别;因子分析结果中的第一个公因子主要反映抑炎介质,而第二、三个公因子主要反映不同的促炎介质,提示了炎症介质组的变化特点。
Objective:
"Inflammatory Mediatorome",usually highly expressed during inflammation, were all mediators of inflammation in a cell or tissue in one time-phase.As an organic whole,mediators of inflammation,closely linked in function,were called "mediatorome" In this research,several kinds of protein were selected to study from a great deal kinds of protein.Because studying target was limited in a small circumscription,experimental detection could be finished by precise technique and data processing would be easy.This strategy was helpful to resolve problems both in experimental techniques and data processing and very important in TCM research by holistic cellular biology techniques.
Uncontrolled inflammation in systemic inflammatory response syndrome(SIRS) was actually a mediator disease,mainly caused by chain reaction of cytokine.But up to now,no anti-mediator therapy had made sure effect in treating septic shock.There were two possible reasons.First,there were so many kinds of mediator of inflammation that pathogenetic condition could not be improved by treating only a few mediators.Second,mediators of inflammation could protect the body in septic shock and anti-mediator therapy could destroy the protection.
For the first reason,many kinds of mediators of inflammation should be treated together。For the second reason,every mediator in every time-phase should be treated correctly and moderately instead of being simply cleaned up.Exactly treating many kinds of mediators together was a ideal strategy, which was called "mediatorome regulating".TCM could regulate the mediatorome because of its integrity characteristics.Decoction for clearing away pestilent factors and detoxification(DCPD) and Xingnaojing injection(XNJI) had sure therapeutic effect to exogenous febrile disease and could affect mediators.In this research,SIRS experimental animals were treated by DCPD and XNJI while the change of mediatorome was observed and analyzed.
Method:
This research,in which SIRS experimental animals were treated by DCPD and XNJI while many kinds of mediator of inflammation were detected,included 4 experiments.
In "experiment 1",New Zealand rabbits received LPS injection of different times and different doses to indue different exogenous febrile disease model.
In "experiment 2",New Zealand rabbits SIRS models were induced by twice(with a 24-hour interval) lipopolysaccharide(LPS) infusion through vein.SIRS rabbits received intragastric administration of DCPD containing different dose of gypsum.Symptoms and objective signs,such as rectal temperature,consciousness,skin and mucosa,were observed at 1,2.5 and 5.5 hour after dosage and blood samples were collected at 1 and 2.5 hour after dosage.Then,10 kinds of cytokines,including interleukin1(IL-1), interleukin4(IL-4),interleukin6(IL-6),interleukin10(IL-10), interleukin12(IL-12),interleukin13(IL-13),interleukin18(IL-18),tumor necrosis factor-α(TNF-α),interferon-γ(INF-γ) and transforming growth factor(TGF-β1),were tested by enzyme linked immunosorbent assay.Samples of lung and liver were got for pathological section at the end of experiment.
In "experiment 3",SIRS models,indueed in the same way,received XNJI intravenous injection in ear vein.Symptoms and objective signs,such as rectal temperature,consciousness,skin and mucosa,were observed at 1,2.5 and 5.5 hour after dosage and blood samples were collected at 1 and 2.5 hour after dosage.Then,10 kinds of cytokines,including IL-1,IL-4,IL-6,IL-10,IL-12, IL-13,IL-18,TNF-α,INF-γand TGF-β1,were tested by enzyme linked immunosorbent assay.Samples of lung and liver were also got for pathological section.
In "experiment 4",the level of inflammatory mediators and rectal temperature of 49 rabbits in other three experiments were analyzed through bivariate correlate,partial correlate,hierarchical cluster,factor date reduction,linear regression and Logistic regression to explore the variation rule of inflammatory mediatorome.
Results:
In the different-dose injecting experiment,the first LPS injection caused fever,less activity,lassitude and tachypnea in rabbits,then similar symptoms accompanied with prolonged venous hemorrhage time were found after the second injection.As the LPS dose increasing,pathogenetic condition intensified.Large-dose LPS injection caused endotoxin shock symptoms such as unconsciousness and ice cold ears,possibly causing death.In the multiple injecting experiment,injection with equal dose or progressively increasing dose could induce fever every time during 7 days.In the validity proving experiment,all the 38 rabbits had fever after first injection and 2 rabbits died in 24 hours,then all the remained 36 rabbits had fever again after second injection and no rabbit died in next 48 hours.
The DCPD treated groups received intragastric administration of DCPD containing different dose of gypsum.Rectal temperature of both the little-dose and large-dose DCPD group was lower than the controlled group at 1h and 2.5h after dose and there was statistical significance in the difference. At 1h after dose,TNF-αlever of the large-dose DCPD group was lower than the controlled group while TGF-β1 lever was higher,the difference was statistically significant.Lever of inflammatory mediators in little-dose DCPD group was usually between the controlled group and large-dose DCPD group, while lever of inflammatory mediators in the controlled group was never between the little-dose and large-dose DCPD group.At 2.5h after dose,TNF-αlever of large-dose DCPD group was significantly lower than the controlled group, while IL-4 lever of both the little-dose and large-dose DCPD group was higher than the controlled group,the difference is nearly significant(P= 0.056).Lever of inflammatory mediators in little-dose DCPD group was usually between the other 2 groups.
Rectal temperature of the XNJI treated group was significantly lower than the controlled group at 1h and 2.5h after dose.At 1h after dose,TNF-αlever of the XNJI treated group was lower than the controlled group and IL-18 lever was higher,the difference was statistically significant.At 2.5h after dose, no statistical significance was obtained in all the inflammatory mediators between 2 groups.
Variation tendency of inflammatory mediators in all the treated groups was compared to the controlled group and variation of inflammatory mediatorome showed some regularity.For the 2 DCPD treated groups,the direction of variation of all the inflammatory mediators at different time-phase was almost same.According to Pearson coefficient correlation,Spearman coefficient correlation and partial coefficient correlation,positive correlation was found between pro-inflammatory mediators and between anti-inflammatory mediators,but correlation between pro-inflammatory mediators and antiinflammatory mediators was complicated.The coefficient correlation was high between several mediators.In a 9-step clustering analysis,IL-12 and IL-13 were clustered at the first step,IL-12,IL-13 and TGF-β1 were clustered at the second step,while TNF-αwas clustered with other inflammatory mediators at the last step.3 common factors were obtained in factor analysis.The first common factor included IL-12、IL-13、TGF-β1 and IL-4,the second common factor included IFN-γ、TNF-α、IL-18 and IL-10,while the last common factor consisted IL-1、IL-6 and IL-10.Regression equations obtained by linear regression and logistic regression were statistically significant,but coefficients of determination were poor and only a few variables had statistical significance.
Conclusion:
LPS injection could surely cause fever.LPS injection with different times and different doses could indue different exogenous febrile disease models of Weifen,qifen,yingfen and xuefen syndrome.Weifen and qifen syndrome could be endued by LPS infusion once,yingfen and xuefen syndrome could be endued by twice(with a 24-hour interval) LPS infusion,persistent qifen syndrome or deficiency of liver-yin and kidney-yin syndrome by multiple times infusion and unconsciousness and collapse syndrome could be caused by large-dose LPS injection.
The results showed that DCPD containing different dose of gypsum gave antipyretic effect on SIRS rabbits and DCPD containing large dose of gypsum gave more obvious antipyretic effect.DCPD could antagonise inflammation possibly by restraining TNF-αand promoting TGF-β.All the data of inflammatory mediators showed regularity.DCPD with different dose of gypsum caused inflammatory mediators changing in the same direction and the effect of DCPD with large dose of gypsum was more obvious.
The results showed that XNJZ also gave antipyretic effect on SIRS rabbits and antagonised inflammation possibly by restraining TNF-α,but the reason about promoting IL-18 was unknowed.
Some variation characteristic of inflammatory mediatorome was revealed through several multivariate statistical analyzing.The regularity of variation of inflammatory mediators suggested that action mechanism of different treating drugs could be similar.Correlation analysis demonstrated that inflammatory mediators had close relationship.Clustering analysis showed that numerical data of IL-12,IL-13 and TGF-β1 was very similar and data characteristic of TNF-αwas quite different.3 common factors were obtained in factor analysis.The first common factor mainly reflected anti-inflammatory mediators,while the second and third common factors probably reflected different pro-inflammatory mediators.
引文
[1]Richard J Reece.Analysis of Genes and Genomes(刘树林主译),北京:北京大学医学出版社,2006,第1版:212-217,130-132.
[2]刘秉文,陈俊杰.医学分子生物学,北京:中国协和医科大学出版社,2005,第1版:1,532.
[3]乌正赉.现代药学、预防医学及中医进展·公共卫生分册,北京:科学技术文献出版社,2006,第1版:35.
[4]Balk RA.Optimum treatment of severe sepsis and septic shock:evidence in support of the recommendations.Dis Mon,2004;50(4):168-213.
[5]蒋建新,姚咏明,郑江.细菌内毒素基础与临床,北京:人民军医出版社,2004:73-74,81,413-415,188-190,168.
[6]林慧,余林中,秦清和.凉膈散对内毒素肺损伤小鼠肺组织核因子-κB活性的影响.四川中医,2004;22(7):16-18.
[7]Ikezoe T,Yang Y,Heber D,et al.PC-SPES:A Potent Inhibitor of Nuclear Factor-κb Rescues Mice from Lipopolysaccharide-Induced Septic Shock.Mol Pharmacol,2003;64(6):1521-1529.
[8]杨光田,王进.醒脑静对内毒素致大鼠全身炎症反应综合征的影响.中国药学杂志,2006:41(15):1142-1144.
[9]马宏博,姜良铎,朱陵群.扶正排毒液治疗内毒素休克实验研究.中国中医急症,2006;15(3):283-284.
[10]马宏博,刘清泉,姜良铎,等.扶正排毒液对内毒素休克肺损伤家兔支气管肺泡灌洗液和血清细胞因子含量的影响.中国中西医结合急救杂志,2005:12(6):369-372.
[11]谭燚,陆付耳,徐丽君,等.黄连解毒汤对2型糖尿病大鼠血清炎性介质和标志物水平的影响.中国医院药学杂志,2005:25(12):1113-1115.
[12]谭燚,陆付耳,徐丽君,等.黄连解毒汤对2型糖尿病大鼠细胞因子IL-4和IL-10水平的影响.微循环学杂志,2005;15(3):44-45,49.
[13]刘友章,王昌俊,刘静,等.四君子汤对脾虚大鼠肝、心肌、胃黏膜和骨骼肌细胞线粒体损伤的修复作用.中国临床康复,2006:10(39):170-173.
[14]杨爽,张一昕,苗冬雪.人参强心滴丸治疗大鼠心力衰竭的作用机制研究.山东医药,2006:46(25):13-15.
[15]Rice TW.Treatment of severe sepsis:where next? Current and future treatment approaches after the introduction of drotrecogin alfa.Vasc Health Risk Manag,2006;2(1):3-18.
[16]Dinarello CA.Anti-cytokine therapies in response to systemic infection.J Investig Dermatol Symp Proc,2001;6(3):244-250.
[17]陈主初,郭恒怡,王树人,等.病理生理学,北京:人民卫生出版社,2005,第1版:207.
[18]Cain BS,Meldrum DR,Dinarello CA,et al.Tumor necrosis factor-alpha and interleukin-1 beta synergistically depress human myocardial function.Crit Care Med,1999;27(7):1309-1318.
[19]Suputtamongkol Y,Intaranongpai S,Smith MD,et al.A double-blind placebo-controlled study of infusion oflexipafant(Platelet-activating factor receptor antagonist) in patients with severe sepsis.Antimicrob Agents Chemother,2000;44(3):693-696.
[20]Hasko G,Virag L,Egnaczyk G,et al.The crucial role of IL-10 in the suppression of the immunological response in mice exposed to staphylococcal enterotoxin B.Eur J Immunol,1998;28(4):1417-1425.
[21]Nakamura S,Otani T,Ijiri Y,et al.IFN-gamma-dependent and independent mechanisms in adverse effects caused by concomitant administration of IL-18and IL-12.J Immunol,2000;164(6):3330-3336.
[22]Worrall NK,Chang K,Lejeune WS,et al.TNF-alpha causes reversible in vivo systemic vascular barrier dysfunction via NO-dependent and independent mechanisms.Am J Physiol,1997;273(6Pt2):H2565-2574.
[23]Dinarello CA.Proinflammatory cytokines.Chest,2000,118(2):503-508
[24]Kumar A,Kumar A,Paladugu B,etal.Transforming growth factor-betal blocks in vitro cardiac myocyte depression induced by tumor necrosis factor-alpha,interleukin-lbeta,and human septic shock serum.Crit Care Med,2007;35(2):358-364.
[25]Keh D,Spung CL.Use of corticosteroid therapy in patients with sepsis and septic shock:an evidence-based review.Crit Care Med,2004;32(11Suppl):S527-533.
[26]Loisa P,Parviainen I,Tenhunen J,et al.Effect of mode of hydrocortisone administration on glycemic control in patients with septic shock:a prospective randomized trial.Crit Care,2007;11(1):R21.
[27]Sprung CL,Annane D,Keh D,etal.Hydrocortisone therapy for patients with septic shock.N Engl J Med,2008;358(2):111-124.
[28]Marti-Carvajal A,Salanti G,Cardona A.Human recombinant activated protein C for severe sepsis.Cochrane Database Syst Rev,2008;(1):CD004388.
[29]Kanakura H,Taniguchi T.The antiinflammatory effects of propofol in endotoxemic rats during moderate and mild hypothermia.J Anesth,2007;21(3):354-360.
[30]朱团结,董光茄,黄国庆,等.生长抑素对内毒素诱导感染性休克大鼠血清炎症介质的影响.中华医学杂志,2007;87(5):345-347.
[31]Pesta(?)a D,Casanova E,Villagr(?)n MJ,etal.Continuous hemofiltration in hyperthermic septic shock patients.J Trauma,2007;63(4):751-756.
[32]Bock KR.Renal replacement therapy in pediatric critical care medicine.Curr Opin Pediatr,2005;17(3):368-371.
[33]Page M,Hayi-Slayman D,Ber CE,etal.Use of coupled plasma filtration adsorption for septic shock treatment.Ann Fr Anesth Reanim,2007;26(11):990-993.
[34]Mazolewski PJ,Barber A,Williams S,etal.Attenuating tumor necrosis factor alpha does not ameliorate other cytokine and peroxidase products during sepsis.Am J Surg,1999;178(6):556-559.
[35]Murphey ED,Traber DL.Pretreatment with tumor necrosis factor-alpha attenuates arterial hypotension and mortality induced by endotoxin in pigs.Crit Care Med,2000;28(6):2015-2021.
[36]林培政.温病学,北京:中国中医药出版社,2003,第1版:145.
[37]高蓉,柳涌.达原饮治疗病毒感染性发热42例.中国中医急症,2007;16(11):1357.
[38]黄健,闫莉莉.柴胡达原饮治疗流行性感冒100例观察.内蒙古中医药,2005;24(5):26-67.
[39]林邦强.新加达原饮治疗肠伤寒高热64例.河北中医,2003;25(12):924.
[40]王灿辉.从“截断疗法”谈温病治则问题.江苏中医,1997;18(3):3.
[41]马健.试论温病先兆症.中国中医急症,1996;5(1):23-25.
[42]王秀莲.论温病“截断疗法”的内涵与途径.中医药学刊,2001;19(4):338-339.
[43]范学工,龙云铸.禽流感.临床内科杂志,2005;22(8):516-518.
[44]郝向春,马素娟.清瘟败毒饮治疗流行性出血热120例临床观察.中国中西医急救杂志,2003;8(1):45-46.
[45]覃小兰,韩凡,庞嶷.中西医结合治疗流脑5例总结.四川中医,2006;24(2):51-52.
[46]党世录,赵红斌.应用清瘟败毒饮加减治疗重症流感124例.中国社区医生,2005;21(22):40.
[47]陈益昀,石占成,石秀英等.清瘟败毒饮加减治疗传染性非典型肺炎28例临床观察.河北中医,2003;25(11):805-806.
[48]谢恬,凌一揆.清瘟败毒饮对内毒素诱发家兔气血两燔证的疗效和机理.中国中西医结合杂志,1993;13(2).94-97.
[49]佟海岩.浅谈中药的量效关系.贵阳中医学院学报,2005;27(3):48-49.
[50]岳玉萍.辨证施用重剂生石膏治疗热症临床体会.河北中医,2003;25(9):689-690.
[51]尚学瑞,赵世运.重用生石膏为主治疗急性热病.中医研究,2003;16(4):55.
[52]陈齐鸣.重用生石膏治疗超高热疾病的体会.江苏中医,2001;22(10):21.
[53]李榕,陈耀.重用生石膏治疗外感高热124例.中国农村医学,1998;26(4):47-48.
[54]时钧华,魏文章.生石膏对实验致热家兔的退热作用研究.药学通报,1983;18(11):32.
[55]彭胜权.温病学,北京:人民卫生出版社,2000,第6版:1174-1175,1193-1194,1187-1188.
[56]史艳萍,丁选胜,戴德哉.人参白虎汤对链脲佐菌素诱导的糖尿病大鼠血管舒缩功能的影响.中国医科大学学报,2004;35(4):344-348.
[57]郑家锵,戴锦成,杨竣联,等.人参白虎汤加减方对糖尿病大鼠血糖及免疫功能影响的实验研究.福建中医学院学报,2001;11(1):40-43.
[58]余林中,吴锐,黄泳等.凉膈散对家兔内毒素温病模型体温、血浆TNF-α及脑脊液PGE_2、cAMP含量的影响.中国中医药科技,1996;3(4):26-27.
[59]江爱达,余林中,林慧,等.凉膈散对LPS诱导的巨噬细胞丝裂素活化蛋白激酶p38活性的影响.中国中医基础医学杂志,2005;11(7):511-513,518.
[60]曾仲意,张丽芬,冯健兰,等.犀角地黄汤化裁方对蛇伤患者血浆TT、PT、APTT的影响.蛇志,2005;17(2):76-78.
[61]许济群,王绵之.方剂学,上海:上海科学技术出版社,1993,第4版:121-122.
[62]鲁兆麟.中国医学名著珍品全书(下)·温病条辨,沈阳:辽宁科学技术出版社,1995,第1版:53-72.
[63]雷载权.中药学,上海:上海科学技术出版社,1995,第6版:270-272,56,200-201.
[64]张伯臾.中医内科学,上海:上海科学技术出版社,1993,第4版:210.
[65]王蕾,郭洪志,相守武等.醒脑静对急性重症脑出血致全身炎症反应综合征的早期干预研究.中华老年多器官疾病杂志,2007;6(6):389-391,395.
[66]王光炜.醒脑静注射液治疗急性高血压性脑出血疗效观察.中西医结合心脑血管病杂志,2007;5(2):160-161.
[67]楼东东,关亚新,高宏伟.醒脑静注射液对脑出血病人高热昏迷的疗效观察,牡丹江医学院学报,2001;22(1):12-13.
[68]贾维刚,张燕.醒脑静注射液治疗急性脑出血疗效观察.中西医结合心脑血管病杂志,2005;3(10):934-935.
[69]邬军锋,祖衡兵,陈英辉.醒脑静治疗125例重症脑梗死的随机对照分析.神经疾病与精神卫生,2007;7(6):442-444.
[70]吴玉生,姜立平,王占奎等.醒脑静注射液对急性大灶性脑梗塞患者血清肿瘤坏死因子、可溶性血管细胞粘附分子-1的影响.中药药理与临床,1999;15(5):45-46.
[71]皮敏,饶晓丹,曹雪梅等.醒脑开窍法对卒中后抑郁及神经功能康复的影响.江西中医药,2007;38(7):25-26.
[72]刘纳新.醒脑静与路路通治疗急性脑梗死80例疗效观察.现代中西医结合杂志,2008;17(11):1625-1626.
[73]祖衡兵,邬军峰,赵永飞等.醒脑静治疗64例重症脑梗死的临床疗效观察,中国医院药学杂志,2007;27(3):366-368.
[74]陈新鑫,范华昌.醒脑静治疗脑梗塞所致老年痴呆症临床观察.上海中医药杂志,1999;(5):13-15.
[75]高兰平,邵亮.精氨酸联合醒脑静注射液治疗肝性脑病疗效观察,现代中西医结合杂志,2008;17(5):711.
[76]陈庆,文菊,杜建霖.醒脑静注射液治疗慢性阻塞性肺疾病合并肺性脑病疗效观察.中药药理与临床,2008;24(2):101-102.
[77]周晓燕,阎风祥,高淑红等.醒脑静注射液治疗有机磷农药中毒意识障碍的疗效观察.中西医结合实用临床急救,1998;5(5):213-214.
[78]刘乡,李慧,卞继芳等.醒脑静联合纳洛酮治疗阿片类药物中毒45例临床观察.河南中医学院学报,2004;19(3):66-67.
[79]高漾.醒脑静治疗安定中毒的临床观察.华西医学,2008;23(1):28-29.
[80]赵继芬.醒脑静与纳洛酮联合治疗急性酒精中毒的疗效观察.中国实用医药,2008;3(3):3.
[81]张建军,朱镇宇,张俊等.醒脑静注射液在治疗重症颅脑损伤中抗高热和促醒作用的疗效观察.中西医结合实用临床急救,1999;6(1):5-7.
[82]方勇,倪毓生.加用醒脑静治疗蝮蛇咬伤后意识障碍临床观察.广西中医药,2005;28(3):22.
[83]吴志洲,邱德群.醒脑静注射液治疗电击伤20例.中医研究,1999;12(6):23-24.
[84]刘红冬,郭美华,张丽娜.纳洛酮与醒脑静注射液联合治疗病毒性脑炎的疗效观察.中国热带医学,2006;6(1):87,201.
[85]姜淑华,王英杰.醒脑静注射液治疗小儿病毒性脑炎的疗效观察.滨州医学院学报,2002;25(4):299.
[86]廖彩霞,潘爱松.醒脑静在治疗病毒性脑炎中抗高热和促醒作用的观察.浙江中医学院学报,2000;24(5):30.
[87]孙强英.小儿流行性腮腺炎脑膜脑炎106例临床观察.吉林中医药,1998;(2):2.
[88]梁惕湖,卢罗生.干扰素-α联合醒脑静治疗流行性乙型脑炎的疗效观察.广东药学,2004;14(2):44-45.
[89]张撰荣.脑活素与醒脑静治疗乙型脑炎.医药论坛杂志,2008;29(11):72-73.
[90]顾伟玲.醒脑静注射液治疗流行性乙型脑炎31例.中西医结合心脑血管病杂志,2007;5(6):547-548.
[91]韩树芬.中西医结合治疗急性单纯疱疹病毒性脑炎8例.临床荟萃,2002;17(21):1281.
[92]谭亚萍,何永峰.清开灵醒脑静配合抗结核药治疗结核性脑膜炎18例.辽宁中医杂志,2007;34(2):182-183.
[93]杨明辉.醒脑静注射液配合抗疟药治疗脑型疟疾35例.云南中医中药杂志,2008;29(5):39.
[94]王春燕.醒脑静脉注射液预防小儿热性惊厥复发的疗效观察.江西医学院学报,1999;39(6):147-148.
[95]贾慧群,余加林,贾建新.醒脑静对儿童高热退热疗效观察.医药导报,2001;20(7):437.
[96]张趁意,刘天杰.醒脑静治疗急性重症中暑28例.人民军医,2005;48(7):399-400.
[97]陆双军.醒脑静注射液治疗红斑狼疮22例临床体会.安徽中医临床杂志,2002;14(1):12-13.
[98]陈晓武,廖旭锋,万里等.醒脑静注射液治疗烧伤脓毒症的临床观察.中国医师杂志,2005;7(1):68-69.
[99]杨秀露,徐玮一,龚跃新,等.醒脑静注射液的药理作用研究.中国药房,1993;4(1):18-19.
[100]崔玲,任云城,孙纪峰等.醒脑静注射液对正常人脑电图的影响.山东中医药大学学报,2002;26(2):125-126.
[101]周红宇,胡国新.醒脑静注射液对小鼠记忆功能的保护作用.四川生理科学杂志,2002;24(1):15-17.
[102]吴玉生,张文高,郑国玲等.醒脑静注射液对急性脑缺血大鼠炎症反应及病理的影响.山东大学学报(医学版),2007;45(7):746-748.
[103]陈寿权,王万铁,王明山等.醒脑静对家兔脑缺血再灌流时TNF、IL-1β、IL-6水平及脑超微结构影响的实验研究.中国急救医学,2000;20(11):637-639.
[104]苗榕生,张晓明,王红彦.醒脑静对急性脑梗塞患者细胞粘附分子及T细胞亚群的影响,北京中医药大学学报,2001;24(1):64-65,71.
[105]陈庆明.醒脑静注射液的药理基础与临床应用.中西医结合实用临床急救,1999;6(4):191.
[106]薛玉榕,王开宇,阮观忠,等.醒脑静治疗脑外伤昏迷38例临床观察.福建中医药,1997;28(4):29.
[107]刘国华,阎瑞平,郑晓丽,等.醒脑静注射液对早期血管性痴呆患者智能及血脂蛋白的影响.中西医结合实用临床急救,1999;6(5):219.
[108]张红波,代建峰,张宾辉.醒脑静注射液对脑缺血再灌注氧化损伤的实验研究.浙江中医药大学学报,2006;30(3):233-234,237.
[109]施春眉.醒脑静对中风患者血浆过氧化脂质的影响.中国中医急症,1998;7(4):29.
[110]万文成,罗海燕,陈洁文等.清热解毒开窍醒脑防治脑缺血的实验研究.深圳中西医结合杂志,2001;11(1):5-7.
[111]徐敬田,马承泰.醒脑静合生脉注射液对脑出血急性期患者PAg、CD62P的影响.山东中医杂志,2002;21(4):207-209.
[112]曾祥国,陈钦材,周幼斌,等.实验性温病卫、气、营、血四个时相的病理变化.四川医学,1983;4(3):129-133.
[113]马健.巴氏杆菌性家兔温病气营传变模型建立的初步研究.中国医药学报,1991;6(2):57-62.
[114]吴仕九,杨运高,杨钦河,等.温病湿热证动物模型的研制及清热祛湿机理的探讨.中国中医药科技,1999;(2):65-67.
[115]朱万孚,陈冠英.生物医学安全与法规,北京:北京大学医学出版社,2007,第1版:35-36.
[116]张文选,孟澍江.大肠杆菌内毒素家兔温病邪入血分之热瘀气脱证模型建立的初步研究.中国医药学报,1990,5(4):70-73,67.
[117]杨进,陆平成.家兔“热毒血瘀证”系列动物模型的试制.南京中医药大学学报,1995;11(2):70-71.
[118]仝小林,马骋,朱宏.热厥气脱证动物模型的建立及其动态观察.中国医药学报,1990;5(2):66-68.
[119]王新华.温病湿热证病理造型及实验研究.广州中医学院学报,1990;7(3):182-185.
[120]王秋,杨进.家兔“温病阴虚热盛证”动物模型的实验研究.辽宁中医杂志,1995;22(9):427-429.
[121]翟玉祥,卞惠敏,马健,等.温病营热阴伤证动物模型的建立.中国中医基础医学杂志,1998;4(4):42-44.
[122]徐鑫荣,张家留,郑崇明,等.丹参注射液对内毒素休克兔多器官损伤的保护作用.中华急诊医学杂志,2004;13(10):679-681.
[123]卫国,吕根法,郭毅斌,等.抗内毒素多肽对内毒素休克模型家兔的治疗作用.中国临床药理学与治疗学,2005;10(8):863-865.
[124]周健洪,陈东风,杜少辉,等.牛珀至宝微丸对内毒素休克大鼠脑神经型一氧化氮 合酶表达的影响.中西医结合学报,2005;3(2):115-118.
[125]潘明,陈琼.中医体质、病证研究与代谢组学.上海中医药杂志,2008;42(6):53-54.
[126]张仲林,钟玲,彭成.基因组学与中医药的相关性研究.四川中医,2008;26(4):49-51.
[127]鲁法庭,刘家强,王米渠.中医基因组学的建立阐释.辽宁中医杂志,2008;35(6):835-836.
[128]逯敏,贾妮.证候-体质-基因组学研究模式的探讨.陕西中医学院学报,2008;31(2):3-4.
[129]周忠科,刘家强,王米渠.中医证候基因组学研究的探讨.中华中医药学刊,2008;26(4):826-827.
[130]丁维俊,董婷,曾庆秋,等.从宏基因组学谈中医整体观的现代化.四川中医,2008;26(6):26-28.
[131]彭永德,高国峰,顾彦杰,等.人肾上腺基因表达谱的建立及其功能的新认识.生命科学研究,2005;9(3):272-277.
[132]崔丽娟,赵晓山,罗仁,等运用抑制性消减杂交技术构建糖尿病肾阳虚证DNA消减文库.中国中医基础医学杂志,2006;12(3):192-194.
[133]李玉萍,罗仁,赵晓山,等.狼疮性肾炎肾阴虚证cDNA消减文库的构建.四川中医,2006;24(3):22-24.
[134]刘清华,林丽珠,周岱翰.中医证候基因组学研究进展.中华中医药学刊,2008;26(6):1293-1295.
[135]Mark Schena.Microarray Analysis(张亮主译),北京:科学出版社,2004,第1版:1-4.
[136]程丹,王国文.实用药物与临床.药物基因组学及生物芯片应用.2008;11(2):114-115.
[137]卓少元,方肇勤,管冬元,等.不同中医治法对DEN肝癌大鼠肝脏细胞色素P450超家族的作用.中国中医基础医学杂志,2008;14(2):100-103.
[138]石锦萍,臧志和,辛志伟,等.基因表达谱芯片对乌三颗粒抗Lewis肺癌相关靶基因的分析研究.中国中西医结合杂志,2003;23(7):530-532.
[139]刘晓燕,申维玺,刘玉梅,等.肺癌阴虚证炎性细胞因子基因表达谱的研究.医学研究杂志,2006;35(3):75-76.
[140]Daniel C.Liebler.蛋白质组学导论--生物学的新工具(张继仁主译),北京:科学出版社,2005,第1版:79,7,19.
[141]赵玉芬.生物有机质谱,郑州:郑州大学出版社,2005,第1版:1,序言.
[142]张惠荣,姜玉梅,张威.蛋白质组学研究现状及我国研究实力.中华医学图书情报 杂志,2008;17(4):68-72.
[143]葛圣雷,陈主初,肖志强,等.TGF-α对鼻咽癌CNE2细胞作用的蛋白质组学分析.华中科技大学学报(医学版),2007;36(6):760-763.
[144]秦延江,刘师莲,杨银荣,等.中枢神经系统脱髓鞘疾病脑脊液蛋白质组学研究.山东大学学报(医学版),2008;46(1):9-14.
[145]Emili AQ,Cagney G.Large scale functional analysis using peptide or protein arrays.Nature Biotechnology,2000;18:393-397.
[146]Weinberger SR,Dalmasso EA,Fung ET.Current achievements using protein chip array technology.Curr Opin Chem Biol,2002;6:86-91.
[147]毛华,李路远.蛋白芯片在心血管疾病研究中的现状与进展.中华老年心脑血管病杂志,2008;10(2):153-154.
[148]Brand NJ,Barton PJ.Myocardial molecular biology:an introduction.Heart,2002;87:284-293.
[149]Di Serio F,Amodio G,Ruggieri E,et al.Proteomic approach to the diagnosis of acute coronary syndrome:preliminary results.Clin Chim Acta,2005;357:226-235.
[150]范乃军,盛新华.SELD Ⅰ蛋白质芯片平台在结直肠癌蛋白质组学研究中的应用.中国普通外科杂志,2008;17(4):388-390.
[151]Horninger W,Reissigl A,Rogatsch H,et al.Prostate cancer screening in the Tyrol,Austia:experience and results.Eur J Cancer,2000;36(10):1322-1335.
[152]Paweletz CP,Gillespie JW,Ornstein DK,et al.Rapid protein display profiling of cancer progression directily form human tissue using a protein biochip.Drug Devel Res,2000;49:34-42.
[153]曾年菊,梁清华,陈疆,等.蛋白质组学方法研究TPx在肝风内动证中的表达及关系.中华中医药学刊,2008;26(4):750-752.
[154]李劲平,吴伟康,曾英,等.附子总生物碱对缺血心肌蛋白质组的影响.中南药学,2008;6(1):18-21.
[155]萧梅芳,梁清华,熊新贵,等.高血压脑出血肝阳化风证患者外周血单个核细胞的蛋白质组学研究.实用预防医学,2008;15(3):623-627.
[156]尹耀慧,易振佳,钟广伟,等.平肝潜阳药物治疗甲亢肝阳上亢证大鼠肾上腺差异蛋白质组学分析.中华中医药学刊,2008;26(6):1172-1176.
[157]苗兰,潘映红,任建勋,等.气滞血瘀证模型大鼠血清蛋白质组学初步研究.中国中医基础医学杂志,2008;14(2):106-107.
[158]卢德赵,沃兴德,施孟如,等.肾上腺切除的肾阳虚大鼠肝线粒体蛋白质组的研究. 中国中医基础医学杂志,2008;14(5):350-353.
[159]钟小兰,吕志平,钱令嘉,等.血清蛋白质组学在中医证型研究中的技术优化.四川中医,2006;24(1):9-11.
[160]孙晓敏,李晓勇,靳文,等.亚健康肾阴虚证的血浆蛋白质组学初步研究.四川中医,2008;26(4):7-9.
[161]刘昌孝.代谢组学与医药科学研究.中国医学科学院学报,2007;29(6):712-718.
[162]许会彬,赵莲,尤国兴,等.失血性休克条件下大鼠血浆代谢组学分析.医学分子生物学杂志,2008;5(2):105-109.
[163]罗和古,丁杰,岳广欣,等.大鼠肝郁脾虚证的代谢组学研究.中西医结合学报,2007;5(3):307-313.
[164]Qiu J.A culture in the balance:traditional Chinese medicine and western science face almost irreconcilable differences can systems biology bring them together.Nature,2007;448:126-128.
[165]王喜军,刘莲,孙晖,等.乙醇诱导大鼠肝损伤的代谢组学和茵陈蒿汤的干预研究.中国药理学通报,2008;24(4):452-457.
[166]蒋宁,周文霞,张永祥.应用代谢组学方法研究比较六味及八味地黄汤的作用机理.中药药理与临床,2007;23(5):45.
[167]李林,王建农,任建勋,等.气虚血瘀证大鼠尿液的核磁共振谱代谢组学.科学通报,2007;52(15):1758-1761.
[2]刘秉文,陈俊杰.医学分子生物学,北京:中国协和医科大学出版社,2005,第1版:1,532.
[3]乌正赉.现代药学、预防医学及中医进展·公共卫生分册,北京:科学技术文献出版社,2006,第1版:35.
[4]Balk RA.Optimum treatment of severe sepsis and septic shock:evidence in support of the recommendations.Dis Mon,2004;50(4):168-213.
[5]蒋建新,姚咏明,郑江.细菌内毒素基础与临床,北京:人民军医出版社,2004:73-74,81,413-415,188-190,168.
[6]林慧,余林中,秦清和.凉膈散对内毒素肺损伤小鼠肺组织核因子-κB活性的影响.四川中医,2004;22(7):16-18.
[7]Ikezoe T,Yang Y,Heber D,et al.PC-SPES:A Potent Inhibitor of Nuclear Factor-κb Rescues Mice from Lipopolysaccharide-Induced Septic Shock.Mol Pharmacol,2003;64(6):1521-1529.
[8]杨光田,王进.醒脑静对内毒素致大鼠全身炎症反应综合征的影响.中国药学杂志,2006:41(15):1142-1144.
[9]马宏博,姜良铎,朱陵群.扶正排毒液治疗内毒素休克实验研究.中国中医急症,2006;15(3):283-284.
[10]马宏博,刘清泉,姜良铎,等.扶正排毒液对内毒素休克肺损伤家兔支气管肺泡灌洗液和血清细胞因子含量的影响.中国中西医结合急救杂志,2005:12(6):369-372.
[11]谭燚,陆付耳,徐丽君,等.黄连解毒汤对2型糖尿病大鼠血清炎性介质和标志物水平的影响.中国医院药学杂志,2005:25(12):1113-1115.
[12]谭燚,陆付耳,徐丽君,等.黄连解毒汤对2型糖尿病大鼠细胞因子IL-4和IL-10水平的影响.微循环学杂志,2005;15(3):44-45,49.
[13]刘友章,王昌俊,刘静,等.四君子汤对脾虚大鼠肝、心肌、胃黏膜和骨骼肌细胞线粒体损伤的修复作用.中国临床康复,2006:10(39):170-173.
[14]杨爽,张一昕,苗冬雪.人参强心滴丸治疗大鼠心力衰竭的作用机制研究.山东医药,2006:46(25):13-15.
[15]Rice TW.Treatment of severe sepsis:where next? Current and future treatment approaches after the introduction of drotrecogin alfa.Vasc Health Risk Manag,2006;2(1):3-18.
[16]Dinarello CA.Anti-cytokine therapies in response to systemic infection.J Investig Dermatol Symp Proc,2001;6(3):244-250.
[17]陈主初,郭恒怡,王树人,等.病理生理学,北京:人民卫生出版社,2005,第1版:207.
[18]Cain BS,Meldrum DR,Dinarello CA,et al.Tumor necrosis factor-alpha and interleukin-1 beta synergistically depress human myocardial function.Crit Care Med,1999;27(7):1309-1318.
[19]Suputtamongkol Y,Intaranongpai S,Smith MD,et al.A double-blind placebo-controlled study of infusion oflexipafant(Platelet-activating factor receptor antagonist) in patients with severe sepsis.Antimicrob Agents Chemother,2000;44(3):693-696.
[20]Hasko G,Virag L,Egnaczyk G,et al.The crucial role of IL-10 in the suppression of the immunological response in mice exposed to staphylococcal enterotoxin B.Eur J Immunol,1998;28(4):1417-1425.
[21]Nakamura S,Otani T,Ijiri Y,et al.IFN-gamma-dependent and independent mechanisms in adverse effects caused by concomitant administration of IL-18and IL-12.J Immunol,2000;164(6):3330-3336.
[22]Worrall NK,Chang K,Lejeune WS,et al.TNF-alpha causes reversible in vivo systemic vascular barrier dysfunction via NO-dependent and independent mechanisms.Am J Physiol,1997;273(6Pt2):H2565-2574.
[23]Dinarello CA.Proinflammatory cytokines.Chest,2000,118(2):503-508
[24]Kumar A,Kumar A,Paladugu B,etal.Transforming growth factor-betal blocks in vitro cardiac myocyte depression induced by tumor necrosis factor-alpha,interleukin-lbeta,and human septic shock serum.Crit Care Med,2007;35(2):358-364.
[25]Keh D,Spung CL.Use of corticosteroid therapy in patients with sepsis and septic shock:an evidence-based review.Crit Care Med,2004;32(11Suppl):S527-533.
[26]Loisa P,Parviainen I,Tenhunen J,et al.Effect of mode of hydrocortisone administration on glycemic control in patients with septic shock:a prospective randomized trial.Crit Care,2007;11(1):R21.
[27]Sprung CL,Annane D,Keh D,etal.Hydrocortisone therapy for patients with septic shock.N Engl J Med,2008;358(2):111-124.
[28]Marti-Carvajal A,Salanti G,Cardona A.Human recombinant activated protein C for severe sepsis.Cochrane Database Syst Rev,2008;(1):CD004388.
[29]Kanakura H,Taniguchi T.The antiinflammatory effects of propofol in endotoxemic rats during moderate and mild hypothermia.J Anesth,2007;21(3):354-360.
[30]朱团结,董光茄,黄国庆,等.生长抑素对内毒素诱导感染性休克大鼠血清炎症介质的影响.中华医学杂志,2007;87(5):345-347.
[31]Pesta(?)a D,Casanova E,Villagr(?)n MJ,etal.Continuous hemofiltration in hyperthermic septic shock patients.J Trauma,2007;63(4):751-756.
[32]Bock KR.Renal replacement therapy in pediatric critical care medicine.Curr Opin Pediatr,2005;17(3):368-371.
[33]Page M,Hayi-Slayman D,Ber CE,etal.Use of coupled plasma filtration adsorption for septic shock treatment.Ann Fr Anesth Reanim,2007;26(11):990-993.
[34]Mazolewski PJ,Barber A,Williams S,etal.Attenuating tumor necrosis factor alpha does not ameliorate other cytokine and peroxidase products during sepsis.Am J Surg,1999;178(6):556-559.
[35]Murphey ED,Traber DL.Pretreatment with tumor necrosis factor-alpha attenuates arterial hypotension and mortality induced by endotoxin in pigs.Crit Care Med,2000;28(6):2015-2021.
[36]林培政.温病学,北京:中国中医药出版社,2003,第1版:145.
[37]高蓉,柳涌.达原饮治疗病毒感染性发热42例.中国中医急症,2007;16(11):1357.
[38]黄健,闫莉莉.柴胡达原饮治疗流行性感冒100例观察.内蒙古中医药,2005;24(5):26-67.
[39]林邦强.新加达原饮治疗肠伤寒高热64例.河北中医,2003;25(12):924.
[40]王灿辉.从“截断疗法”谈温病治则问题.江苏中医,1997;18(3):3.
[41]马健.试论温病先兆症.中国中医急症,1996;5(1):23-25.
[42]王秀莲.论温病“截断疗法”的内涵与途径.中医药学刊,2001;19(4):338-339.
[43]范学工,龙云铸.禽流感.临床内科杂志,2005;22(8):516-518.
[44]郝向春,马素娟.清瘟败毒饮治疗流行性出血热120例临床观察.中国中西医急救杂志,2003;8(1):45-46.
[45]覃小兰,韩凡,庞嶷.中西医结合治疗流脑5例总结.四川中医,2006;24(2):51-52.
[46]党世录,赵红斌.应用清瘟败毒饮加减治疗重症流感124例.中国社区医生,2005;21(22):40.
[47]陈益昀,石占成,石秀英等.清瘟败毒饮加减治疗传染性非典型肺炎28例临床观察.河北中医,2003;25(11):805-806.
[48]谢恬,凌一揆.清瘟败毒饮对内毒素诱发家兔气血两燔证的疗效和机理.中国中西医结合杂志,1993;13(2).94-97.
[49]佟海岩.浅谈中药的量效关系.贵阳中医学院学报,2005;27(3):48-49.
[50]岳玉萍.辨证施用重剂生石膏治疗热症临床体会.河北中医,2003;25(9):689-690.
[51]尚学瑞,赵世运.重用生石膏为主治疗急性热病.中医研究,2003;16(4):55.
[52]陈齐鸣.重用生石膏治疗超高热疾病的体会.江苏中医,2001;22(10):21.
[53]李榕,陈耀.重用生石膏治疗外感高热124例.中国农村医学,1998;26(4):47-48.
[54]时钧华,魏文章.生石膏对实验致热家兔的退热作用研究.药学通报,1983;18(11):32.
[55]彭胜权.温病学,北京:人民卫生出版社,2000,第6版:1174-1175,1193-1194,1187-1188.
[56]史艳萍,丁选胜,戴德哉.人参白虎汤对链脲佐菌素诱导的糖尿病大鼠血管舒缩功能的影响.中国医科大学学报,2004;35(4):344-348.
[57]郑家锵,戴锦成,杨竣联,等.人参白虎汤加减方对糖尿病大鼠血糖及免疫功能影响的实验研究.福建中医学院学报,2001;11(1):40-43.
[58]余林中,吴锐,黄泳等.凉膈散对家兔内毒素温病模型体温、血浆TNF-α及脑脊液PGE_2、cAMP含量的影响.中国中医药科技,1996;3(4):26-27.
[59]江爱达,余林中,林慧,等.凉膈散对LPS诱导的巨噬细胞丝裂素活化蛋白激酶p38活性的影响.中国中医基础医学杂志,2005;11(7):511-513,518.
[60]曾仲意,张丽芬,冯健兰,等.犀角地黄汤化裁方对蛇伤患者血浆TT、PT、APTT的影响.蛇志,2005;17(2):76-78.
[61]许济群,王绵之.方剂学,上海:上海科学技术出版社,1993,第4版:121-122.
[62]鲁兆麟.中国医学名著珍品全书(下)·温病条辨,沈阳:辽宁科学技术出版社,1995,第1版:53-72.
[63]雷载权.中药学,上海:上海科学技术出版社,1995,第6版:270-272,56,200-201.
[64]张伯臾.中医内科学,上海:上海科学技术出版社,1993,第4版:210.
[65]王蕾,郭洪志,相守武等.醒脑静对急性重症脑出血致全身炎症反应综合征的早期干预研究.中华老年多器官疾病杂志,2007;6(6):389-391,395.
[66]王光炜.醒脑静注射液治疗急性高血压性脑出血疗效观察.中西医结合心脑血管病杂志,2007;5(2):160-161.
[67]楼东东,关亚新,高宏伟.醒脑静注射液对脑出血病人高热昏迷的疗效观察,牡丹江医学院学报,2001;22(1):12-13.
[68]贾维刚,张燕.醒脑静注射液治疗急性脑出血疗效观察.中西医结合心脑血管病杂志,2005;3(10):934-935.
[69]邬军锋,祖衡兵,陈英辉.醒脑静治疗125例重症脑梗死的随机对照分析.神经疾病与精神卫生,2007;7(6):442-444.
[70]吴玉生,姜立平,王占奎等.醒脑静注射液对急性大灶性脑梗塞患者血清肿瘤坏死因子、可溶性血管细胞粘附分子-1的影响.中药药理与临床,1999;15(5):45-46.
[71]皮敏,饶晓丹,曹雪梅等.醒脑开窍法对卒中后抑郁及神经功能康复的影响.江西中医药,2007;38(7):25-26.
[72]刘纳新.醒脑静与路路通治疗急性脑梗死80例疗效观察.现代中西医结合杂志,2008;17(11):1625-1626.
[73]祖衡兵,邬军峰,赵永飞等.醒脑静治疗64例重症脑梗死的临床疗效观察,中国医院药学杂志,2007;27(3):366-368.
[74]陈新鑫,范华昌.醒脑静治疗脑梗塞所致老年痴呆症临床观察.上海中医药杂志,1999;(5):13-15.
[75]高兰平,邵亮.精氨酸联合醒脑静注射液治疗肝性脑病疗效观察,现代中西医结合杂志,2008;17(5):711.
[76]陈庆,文菊,杜建霖.醒脑静注射液治疗慢性阻塞性肺疾病合并肺性脑病疗效观察.中药药理与临床,2008;24(2):101-102.
[77]周晓燕,阎风祥,高淑红等.醒脑静注射液治疗有机磷农药中毒意识障碍的疗效观察.中西医结合实用临床急救,1998;5(5):213-214.
[78]刘乡,李慧,卞继芳等.醒脑静联合纳洛酮治疗阿片类药物中毒45例临床观察.河南中医学院学报,2004;19(3):66-67.
[79]高漾.醒脑静治疗安定中毒的临床观察.华西医学,2008;23(1):28-29.
[80]赵继芬.醒脑静与纳洛酮联合治疗急性酒精中毒的疗效观察.中国实用医药,2008;3(3):3.
[81]张建军,朱镇宇,张俊等.醒脑静注射液在治疗重症颅脑损伤中抗高热和促醒作用的疗效观察.中西医结合实用临床急救,1999;6(1):5-7.
[82]方勇,倪毓生.加用醒脑静治疗蝮蛇咬伤后意识障碍临床观察.广西中医药,2005;28(3):22.
[83]吴志洲,邱德群.醒脑静注射液治疗电击伤20例.中医研究,1999;12(6):23-24.
[84]刘红冬,郭美华,张丽娜.纳洛酮与醒脑静注射液联合治疗病毒性脑炎的疗效观察.中国热带医学,2006;6(1):87,201.
[85]姜淑华,王英杰.醒脑静注射液治疗小儿病毒性脑炎的疗效观察.滨州医学院学报,2002;25(4):299.
[86]廖彩霞,潘爱松.醒脑静在治疗病毒性脑炎中抗高热和促醒作用的观察.浙江中医学院学报,2000;24(5):30.
[87]孙强英.小儿流行性腮腺炎脑膜脑炎106例临床观察.吉林中医药,1998;(2):2.
[88]梁惕湖,卢罗生.干扰素-α联合醒脑静治疗流行性乙型脑炎的疗效观察.广东药学,2004;14(2):44-45.
[89]张撰荣.脑活素与醒脑静治疗乙型脑炎.医药论坛杂志,2008;29(11):72-73.
[90]顾伟玲.醒脑静注射液治疗流行性乙型脑炎31例.中西医结合心脑血管病杂志,2007;5(6):547-548.
[91]韩树芬.中西医结合治疗急性单纯疱疹病毒性脑炎8例.临床荟萃,2002;17(21):1281.
[92]谭亚萍,何永峰.清开灵醒脑静配合抗结核药治疗结核性脑膜炎18例.辽宁中医杂志,2007;34(2):182-183.
[93]杨明辉.醒脑静注射液配合抗疟药治疗脑型疟疾35例.云南中医中药杂志,2008;29(5):39.
[94]王春燕.醒脑静脉注射液预防小儿热性惊厥复发的疗效观察.江西医学院学报,1999;39(6):147-148.
[95]贾慧群,余加林,贾建新.醒脑静对儿童高热退热疗效观察.医药导报,2001;20(7):437.
[96]张趁意,刘天杰.醒脑静治疗急性重症中暑28例.人民军医,2005;48(7):399-400.
[97]陆双军.醒脑静注射液治疗红斑狼疮22例临床体会.安徽中医临床杂志,2002;14(1):12-13.
[98]陈晓武,廖旭锋,万里等.醒脑静注射液治疗烧伤脓毒症的临床观察.中国医师杂志,2005;7(1):68-69.
[99]杨秀露,徐玮一,龚跃新,等.醒脑静注射液的药理作用研究.中国药房,1993;4(1):18-19.
[100]崔玲,任云城,孙纪峰等.醒脑静注射液对正常人脑电图的影响.山东中医药大学学报,2002;26(2):125-126.
[101]周红宇,胡国新.醒脑静注射液对小鼠记忆功能的保护作用.四川生理科学杂志,2002;24(1):15-17.
[102]吴玉生,张文高,郑国玲等.醒脑静注射液对急性脑缺血大鼠炎症反应及病理的影响.山东大学学报(医学版),2007;45(7):746-748.
[103]陈寿权,王万铁,王明山等.醒脑静对家兔脑缺血再灌流时TNF、IL-1β、IL-6水平及脑超微结构影响的实验研究.中国急救医学,2000;20(11):637-639.
[104]苗榕生,张晓明,王红彦.醒脑静对急性脑梗塞患者细胞粘附分子及T细胞亚群的影响,北京中医药大学学报,2001;24(1):64-65,71.
[105]陈庆明.醒脑静注射液的药理基础与临床应用.中西医结合实用临床急救,1999;6(4):191.
[106]薛玉榕,王开宇,阮观忠,等.醒脑静治疗脑外伤昏迷38例临床观察.福建中医药,1997;28(4):29.
[107]刘国华,阎瑞平,郑晓丽,等.醒脑静注射液对早期血管性痴呆患者智能及血脂蛋白的影响.中西医结合实用临床急救,1999;6(5):219.
[108]张红波,代建峰,张宾辉.醒脑静注射液对脑缺血再灌注氧化损伤的实验研究.浙江中医药大学学报,2006;30(3):233-234,237.
[109]施春眉.醒脑静对中风患者血浆过氧化脂质的影响.中国中医急症,1998;7(4):29.
[110]万文成,罗海燕,陈洁文等.清热解毒开窍醒脑防治脑缺血的实验研究.深圳中西医结合杂志,2001;11(1):5-7.
[111]徐敬田,马承泰.醒脑静合生脉注射液对脑出血急性期患者PAg、CD62P的影响.山东中医杂志,2002;21(4):207-209.
[112]曾祥国,陈钦材,周幼斌,等.实验性温病卫、气、营、血四个时相的病理变化.四川医学,1983;4(3):129-133.
[113]马健.巴氏杆菌性家兔温病气营传变模型建立的初步研究.中国医药学报,1991;6(2):57-62.
[114]吴仕九,杨运高,杨钦河,等.温病湿热证动物模型的研制及清热祛湿机理的探讨.中国中医药科技,1999;(2):65-67.
[115]朱万孚,陈冠英.生物医学安全与法规,北京:北京大学医学出版社,2007,第1版:35-36.
[116]张文选,孟澍江.大肠杆菌内毒素家兔温病邪入血分之热瘀气脱证模型建立的初步研究.中国医药学报,1990,5(4):70-73,67.
[117]杨进,陆平成.家兔“热毒血瘀证”系列动物模型的试制.南京中医药大学学报,1995;11(2):70-71.
[118]仝小林,马骋,朱宏.热厥气脱证动物模型的建立及其动态观察.中国医药学报,1990;5(2):66-68.
[119]王新华.温病湿热证病理造型及实验研究.广州中医学院学报,1990;7(3):182-185.
[120]王秋,杨进.家兔“温病阴虚热盛证”动物模型的实验研究.辽宁中医杂志,1995;22(9):427-429.
[121]翟玉祥,卞惠敏,马健,等.温病营热阴伤证动物模型的建立.中国中医基础医学杂志,1998;4(4):42-44.
[122]徐鑫荣,张家留,郑崇明,等.丹参注射液对内毒素休克兔多器官损伤的保护作用.中华急诊医学杂志,2004;13(10):679-681.
[123]卫国,吕根法,郭毅斌,等.抗内毒素多肽对内毒素休克模型家兔的治疗作用.中国临床药理学与治疗学,2005;10(8):863-865.
[124]周健洪,陈东风,杜少辉,等.牛珀至宝微丸对内毒素休克大鼠脑神经型一氧化氮 合酶表达的影响.中西医结合学报,2005;3(2):115-118.
[125]潘明,陈琼.中医体质、病证研究与代谢组学.上海中医药杂志,2008;42(6):53-54.
[126]张仲林,钟玲,彭成.基因组学与中医药的相关性研究.四川中医,2008;26(4):49-51.
[127]鲁法庭,刘家强,王米渠.中医基因组学的建立阐释.辽宁中医杂志,2008;35(6):835-836.
[128]逯敏,贾妮.证候-体质-基因组学研究模式的探讨.陕西中医学院学报,2008;31(2):3-4.
[129]周忠科,刘家强,王米渠.中医证候基因组学研究的探讨.中华中医药学刊,2008;26(4):826-827.
[130]丁维俊,董婷,曾庆秋,等.从宏基因组学谈中医整体观的现代化.四川中医,2008;26(6):26-28.
[131]彭永德,高国峰,顾彦杰,等.人肾上腺基因表达谱的建立及其功能的新认识.生命科学研究,2005;9(3):272-277.
[132]崔丽娟,赵晓山,罗仁,等运用抑制性消减杂交技术构建糖尿病肾阳虚证DNA消减文库.中国中医基础医学杂志,2006;12(3):192-194.
[133]李玉萍,罗仁,赵晓山,等.狼疮性肾炎肾阴虚证cDNA消减文库的构建.四川中医,2006;24(3):22-24.
[134]刘清华,林丽珠,周岱翰.中医证候基因组学研究进展.中华中医药学刊,2008;26(6):1293-1295.
[135]Mark Schena.Microarray Analysis(张亮主译),北京:科学出版社,2004,第1版:1-4.
[136]程丹,王国文.实用药物与临床.药物基因组学及生物芯片应用.2008;11(2):114-115.
[137]卓少元,方肇勤,管冬元,等.不同中医治法对DEN肝癌大鼠肝脏细胞色素P450超家族的作用.中国中医基础医学杂志,2008;14(2):100-103.
[138]石锦萍,臧志和,辛志伟,等.基因表达谱芯片对乌三颗粒抗Lewis肺癌相关靶基因的分析研究.中国中西医结合杂志,2003;23(7):530-532.
[139]刘晓燕,申维玺,刘玉梅,等.肺癌阴虚证炎性细胞因子基因表达谱的研究.医学研究杂志,2006;35(3):75-76.
[140]Daniel C.Liebler.蛋白质组学导论--生物学的新工具(张继仁主译),北京:科学出版社,2005,第1版:79,7,19.
[141]赵玉芬.生物有机质谱,郑州:郑州大学出版社,2005,第1版:1,序言.
[142]张惠荣,姜玉梅,张威.蛋白质组学研究现状及我国研究实力.中华医学图书情报 杂志,2008;17(4):68-72.
[143]葛圣雷,陈主初,肖志强,等.TGF-α对鼻咽癌CNE2细胞作用的蛋白质组学分析.华中科技大学学报(医学版),2007;36(6):760-763.
[144]秦延江,刘师莲,杨银荣,等.中枢神经系统脱髓鞘疾病脑脊液蛋白质组学研究.山东大学学报(医学版),2008;46(1):9-14.
[145]Emili AQ,Cagney G.Large scale functional analysis using peptide or protein arrays.Nature Biotechnology,2000;18:393-397.
[146]Weinberger SR,Dalmasso EA,Fung ET.Current achievements using protein chip array technology.Curr Opin Chem Biol,2002;6:86-91.
[147]毛华,李路远.蛋白芯片在心血管疾病研究中的现状与进展.中华老年心脑血管病杂志,2008;10(2):153-154.
[148]Brand NJ,Barton PJ.Myocardial molecular biology:an introduction.Heart,2002;87:284-293.
[149]Di Serio F,Amodio G,Ruggieri E,et al.Proteomic approach to the diagnosis of acute coronary syndrome:preliminary results.Clin Chim Acta,2005;357:226-235.
[150]范乃军,盛新华.SELD Ⅰ蛋白质芯片平台在结直肠癌蛋白质组学研究中的应用.中国普通外科杂志,2008;17(4):388-390.
[151]Horninger W,Reissigl A,Rogatsch H,et al.Prostate cancer screening in the Tyrol,Austia:experience and results.Eur J Cancer,2000;36(10):1322-1335.
[152]Paweletz CP,Gillespie JW,Ornstein DK,et al.Rapid protein display profiling of cancer progression directily form human tissue using a protein biochip.Drug Devel Res,2000;49:34-42.
[153]曾年菊,梁清华,陈疆,等.蛋白质组学方法研究TPx在肝风内动证中的表达及关系.中华中医药学刊,2008;26(4):750-752.
[154]李劲平,吴伟康,曾英,等.附子总生物碱对缺血心肌蛋白质组的影响.中南药学,2008;6(1):18-21.
[155]萧梅芳,梁清华,熊新贵,等.高血压脑出血肝阳化风证患者外周血单个核细胞的蛋白质组学研究.实用预防医学,2008;15(3):623-627.
[156]尹耀慧,易振佳,钟广伟,等.平肝潜阳药物治疗甲亢肝阳上亢证大鼠肾上腺差异蛋白质组学分析.中华中医药学刊,2008;26(6):1172-1176.
[157]苗兰,潘映红,任建勋,等.气滞血瘀证模型大鼠血清蛋白质组学初步研究.中国中医基础医学杂志,2008;14(2):106-107.
[158]卢德赵,沃兴德,施孟如,等.肾上腺切除的肾阳虚大鼠肝线粒体蛋白质组的研究. 中国中医基础医学杂志,2008;14(5):350-353.
[159]钟小兰,吕志平,钱令嘉,等.血清蛋白质组学在中医证型研究中的技术优化.四川中医,2006;24(1):9-11.
[160]孙晓敏,李晓勇,靳文,等.亚健康肾阴虚证的血浆蛋白质组学初步研究.四川中医,2008;26(4):7-9.
[161]刘昌孝.代谢组学与医药科学研究.中国医学科学院学报,2007;29(6):712-718.
[162]许会彬,赵莲,尤国兴,等.失血性休克条件下大鼠血浆代谢组学分析.医学分子生物学杂志,2008;5(2):105-109.
[163]罗和古,丁杰,岳广欣,等.大鼠肝郁脾虚证的代谢组学研究.中西医结合学报,2007;5(3):307-313.
[164]Qiu J.A culture in the balance:traditional Chinese medicine and western science face almost irreconcilable differences can systems biology bring them together.Nature,2007;448:126-128.
[165]王喜军,刘莲,孙晖,等.乙醇诱导大鼠肝损伤的代谢组学和茵陈蒿汤的干预研究.中国药理学通报,2008;24(4):452-457.
[166]蒋宁,周文霞,张永祥.应用代谢组学方法研究比较六味及八味地黄汤的作用机理.中药药理与临床,2007;23(5):45.
[167]李林,王建农,任建勋,等.气虚血瘀证大鼠尿液的核磁共振谱代谢组学.科学通报,2007;52(15):1758-1761.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |